12 NOVEMBER 2020, SYDNEY, AUSTRALIA:
Australian fertility innovator Genea Biomedx
has entered into a collaboration agreement with Hamilton Thorne Ltd, a leading provider of products and services to the Assisted Reproductive Technologies markets. Under the terms of the collaboration agreement, Hamilton Thorne will exclusively commercialize and market Genea Biomedx’s flagship fertility technologies and products in the United States and Canada.
Through this collaboration Genea Biomedx and Hamilton Thorne will build on the existing momentum established by the Fertility Technologies group at EMD Serono in the US and Canada.
“Our mission is to improve ART success rates through the continuing development of standardized technologies. We believe that our unique relationship with Hamilton Thorne will give us the opportunity to further support our existing customers, and to meet the growing demand for our technologies in US and Canada at the same time.” says Louis Villalba, Genea Biomedx CEO.
Genea Biomedx has been developing innovative fertility technologies for automation of laboratory workflows since 2013. Being part of the Genea IVF family has given Genea Biomedx access to valuable resources whose insight and knowledge continuously contribute to converting clinical challenges into new, practical solutions for the modern IVF laboratory.